reports
Beneficient Enters into New GP Primary Capital Transaction
Beneficient Enters into New GP Primary Capital Transaction DALLAS, April 25, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced it has closed on the financing of a $233,333 primary capital commitment for Cork & Vines Fund I, LP (“Fund”), a fund managed by Cork & Vines GP, LP, an asset manager investing in opportunities within the premium ...
Beneficient Reminds Stockholders to Vote on Proxy Proposals Ahead of t...
Beneficient Reminds Stockholders to Vote on Proxy Proposals Ahead of the Company’s Annual Meeting on April 30, 2025 DALLAS, April 23, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben,” or the “Company”), a technology-enabled platform providing exit opportunities, primary capital solutions, and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, reminds stockholders to vote on proxy proposals before the upcoming Annual Meeting of Stockholders at 9:00 a.m. Central Time on April 30, 2025. Stockholder...
Beneficient Adjourns Annual Meeting of Stockholders
Beneficient Adjourns Annual Meeting of Stockholders DALLAS, April 16, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced today that the Company’s Annual Meeting of Stockholders, which had been previously adjourned to 9:00 a.m. Central time today, April 16, 2025, has been once again adjourned to allow for more time for stockholde...
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Announces Leadership Changes NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal...
Beneficient to Present at the Emerging Growth Conference on April 17, ...
Beneficient to Present at the Emerging Growth Conference on April 17, 2025 DALLAS, April 15, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, is pleased to announce that it will present a brief corporate update at the Emerging Growth Conference on Thursday, April 17, 2025. The Company will host a webcast group presentation at 4:10 PM Eastern Time. I...
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VT...
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuti...
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Pr...
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit" or the “Company”) today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value. Under the program, Conduit may repurchase shares from time to time...
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Le...
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has entered into an additional license and...
Beneficient Enters into $9.6 Million GP Primary Capital Transaction
Beneficient Enters into $9.6 Million GP Primary Capital Transaction DALLAS, April 07, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced it has closed on the financing of a $9.6 million primary capital commitment for Pulse Pioneer Fund, LP (“Fund”), a fund managed by Pulse Pioneer GP, LLC, an asset manager that manages venture capital fun...
Beneficient Adjourns Annual Meeting of Stockholders
Beneficient Adjourns Annual Meeting of Stockholders DALLAS, March 31, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced today that the Company’s Annual Meeting of Stockholders, which began at 9:00 a.m. Central time today, March 31, 2025, has been adjourned to allow for more time for stockholders to vote. At this time, there we...
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Ass...
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: ) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that the United States Patent and Trademark Office (USPTO) has granted the...
Conduit Pharmaceuticals Provides Research and Development Update on Pr...
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 19, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company”) today provides an R&D update on the ...
Beneficient Announces Agreement to Settle GWG Litigation
Beneficient Announces Agreement to Settle GWG Litigation DALLAS, March 10, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Beneficient,” “Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, today announced that it has entered into a binding agreement to settle all claims in the previously disclosed lawsuits relating to GWG Holdings, Inc. (“GWG”) in federal court in the Northern District of Texas and t...
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing...
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq”) Hearing Panel (the "Panel”) and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price”), Market Value of Pu...
Conduit Progresses Phase II of its AI Initiative with Sarborg
Conduit Progresses Phase II of its AI Initiative with Sarborg Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug developmentSarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited. Further to the Company’s pr...
Conduit Pharmaceuticals Partners with Charles River in Clinically Rele...
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes.The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). NAPLES, Fla. and CAMBRIDGE, U...
Beneficient Reports Results for Third Quarter Fiscal 2025
Beneficient Reports Results for Third Quarter Fiscal 2025 Announced Proposed Transaction to Increase Tangible Book Value to Ben Public Company Stockholders by $9 Million on 8.4 Million Shares Outstanding, Permanent Equity Increased by $35 Million Completed First Primary Capital Transaction as Part of Ongoing Business Development Activities Announced Proposed International Bank Acquisition to Expand Alternative and Digital Asset Markets Capabilities DALLAS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing ...
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversio...
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Conduit” or the “Company”), today announces the repayment of its $600,000 promissory note (the “Note”) to Nirland Limited (“Nirland”) and provided an update on the conversion of its Senior Secured Promissory Note (the “Senior Note”) with Nirland. On February 7, 2025, Conduit repaid the final balance of the Note in full, satisfying all obligations under the agreement. The Note, issued on October 28, 2024, ...
Beneficient Announces Third Quarter Fiscal 2025 Earnings Release and W...
Beneficient Announces Third Quarter Fiscal 2025 Earnings Release and Webcast DALLAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, announced that it will release its Third Quarter Fiscal 2025 financial results on Thursday, February 13, 2025. Beneficient will host a webcast to present the results on Thursday, February 13, 2025 at 8:30 a.m. ...
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaborati...
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: (“Conduit” or the “Company”), today announces the successful completion of all mile...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.